G17dt (Not yet branded)
Other Medications
Description
G17DT is an immunotherapeutic vaccine that targets gastrin-17, a hormone that promotes growth of certain gastrointestinal cancers including colorectal carcinoma. The vaccine consists of gastrin-17 conjugated to diphtheria toxoid to stimulate an immune response against gastrin-producing cells. G17DT has been evaluated in colorectal cancer patients both as monotherapy and in combination with chemotherapy agents like irinotecan.
Mechanism of Action
G17DT works by inducing antibodies against gastrin-17, a gastrointestinal hormone that stimulates cell proliferation and angiogenesis in colorectal tumors. By neutralizing gastrin-17, the vaccine aims to reduce tumor growth signals and potentially slow cancer progression.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Intramuscular |
| Clinical Trials | 5 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.